Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonate therapy in multiple myeloma

M Laakso1, E Jantunen

  • 1Department of Medicine, University of Kuopio, Finland.

Acta Oncologica (Stockholm, Sweden)
|January 1, 1996
PubMed
Summary

Bisphosphonates effectively manage bone complications in multiple myeloma patients. These therapies reduce bone lesions, fractures, and pain, improving patient outcomes alongside standard cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Bone marrow transplantation·2019
Same author

Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34<sup>+</sup> cells in non-Hodgkin lymphoma patients.

Transfusion·2018
Same author

Preemptive plerixafor injection added to pegfilgrastim after chemotherapy in non-Hodgkin lymphoma patients mobilizing poorly.

Annals of hematology·2017
Same author

Pre-emptive plerixafor injection in lymphoma patients mobilized with chemotherapy plus pegfilgrastim followed by apheresis on the same day.

Journal of clinical apheresis·2017
Same author

A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma.

Bone marrow transplantation·2015
Same author

Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2012

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metabolism

Background:

  • Multiple myeloma frequently causes bone disease, including lytic lesions, fractures, hypercalcemia, and osteoporosis.
  • Effective management of these skeletal complications is crucial for patient well-being.

Purpose of the Study:

  • To evaluate the efficacy of bisphosphonates as an adjunctive therapy for bone disease in multiple myeloma.

Main Methods:

  • Review of placebo-controlled studies investigating bisphosphonates (clodronate, pamidronate) in multiple myeloma patients.
  • Assessment of bisphosphonates' impact on hypercalcemia, bone lesions, pathological fractures, and bone pain.

Main Results:

  • Bisphosphonates corrected hypercalcemia in multiple myeloma patients.
  • Significant reductions in new bone lesions and pathological fractures were observed.
  • Bisphosphonates demonstrated efficacy in relieving bone pain.

Conclusions:

  • Bisphosphonates are a valuable adjunctive therapy for managing skeletal complications in multiple myeloma.
  • These agents improve clinical outcomes by addressing bone disease alongside antimyeloma treatments.

Related Experiment Videos